Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enx108A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,000.0 million
Deal Type : Partnership
Details : Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.
Product Name : Enx108A
Product Type : Antibody
Upfront Cash : $1,000.0 million
September 01, 2020
Lead Product(s) : Enx108A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,000.0 million
Deal Type : Partnership